Revolution Medicines
RVMD
184 hedge funds and large institutions have $4.59B invested in Revolution Medicines in 2023 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 81 increasing their positions, 34 reducing their positions, and 36 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 34
87% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $10.2M
50% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 36
48% more capital invested
Capital invested by funds: $3.11B → $4.59B (+$1.48B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
10% more funds holding
Funds holding: 168 → 184 (+16)
5.24% less ownership
Funds ownership: 102.97% → 97.73% (-5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$127M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$104M |
| 4 |
BlackRock
New York
|
+$98.1M |
| 5 |
CC
Casdin Capital
New York
|
+$93.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$131M |
| 2 |
CG
Column Group
San Francisco,
California
|
-$29.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$20M |
| 4 |
D.E. Shaw & Co
New York
|
-$16.7M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$14.4M |
RVMD Hedge Fund Activity: Q4 2023 in Review
184 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2023, worth a combined $4.59B — up 48% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new RVMD positions and 36 closed out — a net gain of 18 holders — while 81 added to existing stakes and 34 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $127M. The largest seller was EcoR1 Capital, cutting an estimated $131M.
- 184 institutional investors held Revolution Medicines (RVMD) as of Q4 2023, up from 168 in Q3 2023.
- Funds reported $4.59B of Revolution Medicines stock for Q4 2023, up 48% quarter-over-quarter.
- 54 funds opened new Revolution Medicines positions in Q4 2023 and 36 closed out, a net change of +18 holders.
- The largest Revolution Medicines buyer in Q4 2023 was Alphabet Inc, an estimated $127M added.
- The largest Revolution Medicines seller in Q4 2023 was EcoR1 Capital, an estimated $131M sold.
Based on aggregated 13F filings for Q4 2023.